IL-7 variants with reduced immunogenicity

Details for Australian Patent Application No. 2005313492 (hide)

Owner Merck Patent GmbH

Inventors Way, Jeffrey C.; Gillies, Stephen D.

Agent Davies Collison Cave

Pub. Number AU-B-2005313492

PCT Pub. Number WO2006/061219

Priority 60/634,470 09.12.04 US

Filing date 8 December 2005

Wipo publication date 15 June 2006

Acceptance publication date 15 December 2011

International Classifications

C07K 14/54 (2006.01) Peptides having more than 20 amino acids

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

A61P 31/18 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/24 (2006.01) Mutation or genetic engineering

Event Publications

2 August 2007 PCT application entered the National Phase

  PCT publication WO2006/061219 Priority application(s): WO2006/061219

15 December 2011 Application Accepted

  Published as AU-B-2005313492

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005313499-Process for the production of anilines

2005313485-3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors